文献速递免疫规划传染病防控与疫情报告

意大利托斯卡纳地区C群脑膜炎球菌结合疫苗在C/cc11群侵袭性脑膜炎球菌病暴发前及暴发期间的效果

Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
PubMed 文献 · Vaccine · 2018-06-09

在意大利托斯卡纳,2005年引入单价C群脑膜炎球菌结合疫苗(MCC)免疫规划,2015-2016年发生C/cc11高致病株暴发。研究基于2006-2016年监测数据和回顾性队列,估算疫苗有效性(VE)。暴发前VE为100%(95%CI不可估计,p=0.03),暴发期间VE为77%(95%CI 36-92,p<0.01),总体VE为80%(95%CI 54-92,p<0.01)。

要点

  • 2006-2016年报告85例C群侵袭性疾病,其中61例(71.8%)发生在2015-2016年暴发期间。
  • 共发生12例疫苗失败,均发生在暴发期间;接种至发病间隔1例为20天,6例为9个月至3年,5例≥7年。
  • 暴发期间VE为77%(95%CI 36-92,p<0.01),总体VE为80%(95%CI 54-92,p<0.01)。

核心结论

  • 托斯卡纳地区C群脑膜炎球菌疫苗失败仅发生在2015-2016年暴发期间,多数发生在接种后数年;暴发期间VE较高,支持MenC疫苗诱导有效保护。

研究设计与样本

  • 回顾性队列研究,纳入托斯卡纳1994-2014年出生队列人群,基于2006-2016年国家侵袭性细菌性疾病监测系统数据,采用泊松模型估计调整风险比(ARR)并计算VE=1-ARR。

主要发现

  • 2006-2016年报告85例C群侵袭性疾病,其中61例(71.8%)来自2015-2016年。
  • 12例疫苗失败均发生在暴发期间;接种至发病间隔:1例20天,6例9个月至3年,5例≥7年。
  • 暴发前(2006-2014年)VE为100%(95%CI不可估计,p=0.03);暴发期间(2015-2016年)VE为77%(95%CI 36-92,p<0.01);总体VE为80%(95%CI 54-92,p<0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In Tuscany, Italy, where a universal immunization program with monovalent meningococcal C conjugate vaccine (MCC) was introduced in 2005, an outbreak of invasive meningococcal disease (IMD) due to the hypervirulent strain of Neisseria meningitidis C/cc11 occurred in 2015-2016, leading to an immunization reactive campaign using either the tetravalent (ACWY) meningococcal conjugate or the MCC vaccine. During the outbreak, IMD serogroup C (MenC) cases were also reported among vaccinated individuals. This study aimed to characterize meningococcal C conjugate vaccines (MenC-vaccines) failures and to estimate their effectiveness since the introduction (2005-2016) and during the outbreak (2015-2016). METHODS: MenC cases and related vaccine-failures were drawn from the National Surveillance System of Invasive Bacterial Disease (IBD) for the period 2006-2016. A retrospective cohort-study, including the Tuscany' population of the birth-cohorts 1994-2014, was carried out. Based on annual reports of vaccination, person-years of MenC-vaccines exposed and unexposed individuals were calculated by calendar-year, birth-cohort, and local health unit. Adjusted (by birth-cohort, local health unit, and calendar-year) risk-ratios (ARR) of MenC invasive disease for vaccinated vs unvaccinated were estimated by the Poisson model. Vaccine-effectiveness (VE) was estimated as: VE = 1-ARR. RESULTS: In the period 2006-2016, 85 MenC-invasive disease cases were reported; 61 (71.8%) from 2015 to 2016. Twelve vaccine failures occurred, all of them during the outbreak. The time-interval from immunization to IMD onset was 20 days in one case, from 9 months to 3 years in six cases, and ≥7 years in five cases. VE was, 100% (95%CI not estimable, p = 0.03) before the outbreak (2006-2014) and 77% (95%CI 36-92, p < 0.01) during the outbreak; VE was 80% (95%CI 54-92, p < 0.01) during the overall period. CONCLUSIONS: In Tuscany, MenC-vaccine failures occurred exclusively during the 2015-2016 outbreak. Most of them occurred several years after vaccination. VE during the outbreak-period was rather high supporting an effective protection induced by MenC-vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Pezzotti P, Miglietta A, Neri A, et al. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy. Vaccine. 2018. PMID: 29895504. doi:10.1016/j.vaccine.2018.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。